AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has been assigned a $3.00 price target by equities research analysts at Piper Jaffray Companies in a research note issued on Tuesday. The brokerage currently has a “hold” rating on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ target price suggests a potential downside of 18.92% from the company’s current price.

ACRX has been the subject of a number of other research reports. ValuEngine raised AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday. Zacks Investment Research raised AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Wednesday, May 3rd. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $7.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Friday, July 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $7.86.

AcelRx Pharmaceuticals (NASDAQ ACRX) traded down 2.63% during mid-day trading on Tuesday, hitting $3.70. The company had a trading volume of 907,373 shares. AcelRx Pharmaceuticals has a 12 month low of $1.95 and a 12 month high of $4.08. The firm’s market capitalization is $167.91 million. The company has a 50-day moving average price of $2.42 and a 200 day moving average price of $2.72.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.06. The business had revenue of $3.11 million during the quarter, compared to analyst estimates of $2.36 million. AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 273.65%. Equities analysts forecast that AcelRx Pharmaceuticals will post ($1.15) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/07/26/piper-jaffray-companies-reiterates-3-00-price-target-for-acelrx-pharmaceuticals-inc-nasdaqacrx.html.

In other news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the company’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $2.40, for a total value of $2,100,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 28.10% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of the stock. Teachers Advisors LLC raised its stake in AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 8,475 shares during the period. Acadian Asset Management LLC raised its position in shares of AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 32,087 shares during the last quarter. ING Groep NV raised its position in shares of AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock valued at $123,000 after buying an additional 26,000 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after buying an additional 6,942 shares during the last quarter. Institutional investors and hedge funds own 30.32% of the company’s stock.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.